Treatment of acute promyelocytic leukemia: A single institution experience. Tratamiento de la leucemia promielocítica aguda. Experiencia de una sola institución. A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Acute promyelocytic. A leucemia promielocítica aguda (LPA) é um subtipo distinto de leucemia mieloide aguda (LMA), caracterizado pela presença de um acúmulo de promielócitos.
|Published (Last):||4 May 2005|
|PDF File Size:||10.11 Mb|
|ePub File Size:||4.22 Mb|
|Price:||Free* [*Free Regsitration Required]|
The greatest cause of death was severe bleeding, especially in the central nervous system CNS. High frequency of acute promyelocytic leukemia in Mexican mestizos.
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping promielocitixa. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.
CD34 and CD2 expression in acute promyelocytic leukemia. How acute promyelocytic leukaemia revived arsenic. Substantial progress has occurred in the treatment of APL because of improved understanding of the pathophysiology of the disease and identification of a molecular target. Toxicity and survival in de novo patients. The roles of both consolidation therapy with CT including anthracyclines as well as the lsucemia therapy with ATRA, mercaptopurine and methotrexate have been also well defined.
Orphanet: Leucemia promielocitica acuta
A maior causa de morte foi a hemorragia grave, especialmente no sistema nervoso central SNC. Leuk Lymphoma ; Check this box if you wish to receive a copy of your message.
The documents contained in this web site are presented for information purposes only. Flow cytometry in the clinical laboratory.
A report of the Spanish group Pethema. In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia: The molecular pathogenesis of acute promyelocytic leukaemia: Japan Adult Leukemia Study Group. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia AML is feasible: The slightly high mortality rates, especially early mortality, motivate studies to understand this pathology in the Brazilian context.
Am Soc Hematol Educ Program. Morphological and cytochemical characteristics of leukaemic promyelocytes. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Reduced activity of TAFI thrombin-activable fibrinolysis inibitor in acute promyelocytic leukemia. Abnormalities in hemostasis in acute promyelocytic leukemia.
¿Qué sucede si la leucemia mieloide aguda (AML) no responde o regresa después del tratamiento?
Semin Hematol ; Correspondence and reprint request: Other search option s Alphabetical list. Crit Rev Oncol Hematol. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: Epigenetic gene silencing in acute promyelocytic leukemia. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: Mechanisms of all-trans retinoic acid- induced differentiation of acute promyelocytic leukemia cells.
Biological features of primary APL blasts: Targeting FLT3 for the treatment of leukemia. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Treatment of acute promyelocytic leukemia: Acute promyelocytic leukemia as a paradigm for targeted therapy.
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: Acute promyelocytic leukemia; arterial thrombosis; treatment; citogenetic remission. The presumptive diagnosis of APL should be quick, because these patients are at risk for early death. The t 15;17 translocation of acute promyelocitic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.
The development of arterial thrombosis is uncommon.
Tratamiento de la leucemia promielocítica aguda: Experiencia de una sola institución
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. How to cite this article. Differential liganddependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.
Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Vasco de Quiroga No. Treatment of acute promyelocytic keucemia with Arsenic compounds: Cellular immunophenotypes in 97 adults with acute leukemia. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk, More on geographic hematology: Best Pract Res Clin Haematol. In this work a year-old male patient with acute arterial insufficiency was evaluated.
Annu Rev Med ;